Episodios

  • The Great Debate of Steroid Use in CAP
    Jan 5 2026

    Corticosteroids in the treatment of community-acquired pneumonia (CAP) remain a topic of clinical curiosity and mixed opinions. In this unique episode, two expert guests share opposing perspectives—one advocating for corticosteroid use in CAP and the other urging caution—offering pharmacists a balanced view of the current evidence and practice considerations. Tune in to explore both sides of the debate and walk away with insights to inform your role in collaborative patient care.

    HOST
    Rachel Maynard, PharmD

    GameChangers Podcast Host and Clinical Editor, CEimpact
    Lead Editor, Pyrls

    GUESTS
    Sam Markle, PharmD
    Critical Care Pharmacist
    Sanford Health

    Tristan Houle, PharmD
    PGY2 Critical Care Pharmacy Resident
    Sanford Health

    PRACTICE RESOURCE
    Purchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.

    CPE REDEMPTION
    This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

    • If you are already enrolled in this course, click here to redeem your credit.
    • To purchase this episode and claim your CPE credit, click here.

    CPE INFORMATION
    Learning Objectives
    Upon successful completion of this knowledge-based activity, participants should be able to:
    1. Describe current evidence supporting and challenging the use of corticosteroids in the treatment of community-acquired pneumonia (CAP).
    2. Identify key considerations for pharmacists when evaluating corticosteroid use as adjunctive therapy in CAP.

    Rachel Maynard, Sam Markle, and Tristan Houle have no relevant financial relationships to disclose.

    0.05 CEU/0.5 Hr
    UAN: 0107-0000-26-032-H01-P
    Initial release date: 1/5/2026
    Expiration date: 1/5/2027
    Additional CPE details can be found here.

    Follow CEimpact on Social Media:
    LinkedIn
    Instagram

    Más Menos
    37 m
  • The Truth About Cannabis and Pregnancy Outcomes
    Dec 29 2025

    As cannabis becomes more widely available and socially accepted, so does the misconception that it's safe to use during pregnancy and lactation. This course reviews updated guidance from the American College of Obstetricians and Gynecologists (ACOG), highlighting the evidence behind the risks and outlining how pharmacists can address misinformation and counsel patients effectively. You will learn how to support safe, informed decision-making that promotes the health of both parent and child.

    HOST
    Rachel Maynard, PharmD

    GameChangers Podcast Host and Clinical Editor, CEimpact
    Lead Editor, Pyrls

    GUEST
    Kevin Shea, PharmD
    Pharmacist
    Vytal Options


    PRACTICE RESOURCE
    Purchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.


    CPE REDEMPTION
    This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

    • If you are already enrolled in this course, click here to redeem your credit.
    • To purchase this episode and claim your CPE credit, click here.


    CPE INFORMATION
    Learning Objectives
    Upon successful completion of this knowledge-based activity, participants should be able to:
    1. Identify current ACOG recommendations regarding cannabis use during pregnancy and lactation.
    2. Describe pharmacist strategies for screening, counseling, and reducing risks associated with cannabis use during the perinatal period.

    Rachel Maynard and Kevin Shea have no relevant financial relationships to disclose.

    0.05 CEU/0.5 Hr
    UAN: 0107-0000-25-377-H01-P
    Initial release date: 12/29/2025
    Expiration date: 12/29/2026
    Additional CPE details can be found here.

    Follow CEimpact on Social Media:
    LinkedIn
    Instagram

    Más Menos
    43 m
  • Microdose Lithium in Alzheimer's Treatment
    Dec 22 2025

    Recent preclinical studies highlight the potential of micro‑dosed lithium to modulate Alzheimer’s disease pathology and support neuronal health. This episode examines the molecular mechanisms, current evidence in Alzheimer’s models, and emerging considerations for safe use and monitoring. You will gain insights to navigate this evolving topic and support informed discussions around lithium micro‑dosing in Alzheimer’s care.

    HOST
    Rachel Maynard, PharmD

    GameChangers Podcast Host and Clinical Editor, CEimpact
    Lead Editor, Pyrls

    GUEST
    Dawn Gerber, PharmD, BCGP, FASCP, FAzPA, CPAFH
    Professor of Pharmacy Practice
    Midwestern University

    PRACTICE RESOURCE
    Purchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.

    CPE REDEMPTION
    This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

    • If you are already enrolled in this course, click here to redeem your credit.
    • To purchase this episode and claim your CPE credit, click here.


    CPE INFORMATION
    Learning Objectives
    Upon successful completion of this knowledge-based activity, participants should be able to:
    1. Describe current evidence on the use of microdose lithium in Alzheimer's disease.
    2. Identify pharmacist considerations for monitoring, patient selection, and safety in the context of lithium micro-dosing for Alzheimer's.

    Rachel Maynard and Dawn Gerber have no relevant financial relationships to disclose.

    0.05 CEU/0.5 Hr
    UAN: 0107-0000-25-375-H01-P
    Initial release date: 12/22/2025
    Expiration date: 12/22/2026
    Additional CPE details can be found here.

    Follow CEimpact on Social Media:
    LinkedIn
    Instagram

    Más Menos
    39 m
  • New Prescription Option for Fibromyalgia Treatment
    Dec 15 2025

    Patients with fibromyalgia have waited more than a decade for a new therapeutic option, and a recent regulatory approval signals a shift for these patients. This episode reviews the clinical trial data, mechanism of action, dosing considerations, and pharmacist‑relevant monitoring for the newly approved sublingual formulation of cyclobenzaprine HCl. You will gain practical insights to inform patient education, therapy optimization, and interdisciplinary collaboration in fibromyalgia care.

    HOST
    Rachel Maynard, PharmD

    GameChangers Podcast Host and Clinical Editor, CEimpact
    Lead Editor, Pyrls

    GUEST
    Amanda (Mandy) Mullins, PharmD, BCPS

    Clinical Pharmacist Practitioner
    Veterans Affairs

    PRACTICE RESOURCE
    Purchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast

    CPE REDEMPTION
    This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

    • If you are already enrolled in this course, click here to redeem your credit.
    • To purchase this episode and claim your CPE credit, click here.


    CPE INFORMATION
    Learning Objectives
    Upon successful completion of this knowledge-based activity, participants should be able to:
    1. Describe the mechanism of action and key clinical trial outcomes associated with the newly approved prescription medication for fibromyalgia.
    2. Identify pharmacist responsibilities for dosing, monitoring adverse effects, and patient counseling when supporting the use of this new fibromyalgia therapy.

    Rachel Maynard and Amanda (Mandy) Mullins have no relevant financial relationships with ineligible companies to disclose.

    0.05 CEU/0.5 Hr
    UAN: 0107-0000-25-371-H01-P
    Initial release date: 12/15/2025
    Expiration date: 12/15/2026
    Additional CPE details can be found here.

    Follow CEimpact on Social Media:
    LinkedIn
    Instagram

    Más Menos
    46 m
  • How OTC Pain Medications May Fuel Antibiotic Resistance
    Dec 8 2025

    Pain relief medications like acetaminophen and ibuprofen are staples in everyday care—but emerging research suggests they may play a role in antibiotic resistance. This episode reviews recent findings, explores how these common drugs may influence bacterial response to antibiotics, and highlights pharmacist‑specific considerations. You will walk away with practical insights to support informed medication use and strengthen antibiotic stewardship.

    HOST
    Rachel Maynard, PharmD
    GameChangers Podcast Host and Clinical Editor, CEimpact
    Lead Editor, Pyrls

    Hunter O. Rondeau, PharmD, BCIDP, AAHIVP
    Antimicrobial Stewardship Coordinator, SSM Health
    Adjunct Clinical Assistant Professor, University of Kansas School of Pharmacy

    Rachel Maynard has no relevant financial relationships with ineligible companies to disclose.

    Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated.

    CPE REDEMPTION
    This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

    • If you are already enrolled in this course, click here to redeem your credit.
    • To purchase this episode and claim your CPE credit, click here.


    CPE INFORMATION
    Learning Objectives
    Upon successful completion of this knowledge-based activity, participants should be able to:
    1. Describe emerging evidence on how common OTC pain medications may influence antibiotic resistance.
    2. Identify pharmacist strategies to optimize analgesic and antibiotic use while supporting antimicrobial stewardship.

    0.05 CEU/0.5 Hr
    UAN: 0107-0000-25-372-H01-P
    Initial release date: 12/8/2025
    Expiration date: 12/8/2026
    Additional CPE details can be found here.

    Follow CEimpact on Social Media:
    LinkedIn
    Instagram

    Más Menos
    38 m
  • Navigating the Role of Leucovorin in Autism Care
    Dec 1 2025

    Recent FDA actions have brought renewed attention to leucovorin as a potential treatment for managing symptoms associated with autism spectrum disorder. This course explores the clinical distinctions between autism and cerebral folate deficiency, reviews key evidence behind leucovorin use, and outlines counseling considerations relevant to pharmacy practice. You will gain clarity on this complex and evolving topic to better support informed, evidence-based care.

    HOST
    Rachel Maynard, PharmD
    GameChangers Podcast Host and Clinical Editor, CEimpact
    Lead Editor, Pyrls

    GUEST
    Geoff Wall, PharmD, FCCP, BCPS
    Professor of Pharmacy Practice
    Iowa Methodist Medical Center

    Rachel Maynard and Geoff Wall have no relevant financial relationships to disclose.


    CPE REDEMPTION
    This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

    • If you are already enrolled in this course, click here to redeem your credit.
    • To purchase this episode and claim your CPE credit, click here.


    CPE INFORMATION
    Learning Objectives
    Upon successful completion of this knowledge-based activity, participants should be able to:
    1. Describe current clinical evidence related to the use of leucovorin in autism and cerebral folate deficiency.
    2. Identify key counseling considerations for pharmacists discussing leucovorin therapy with patients and caregivers.

    0.05 CEU/0.5 Hr
    UAN: 0107-0000-25-363-H01-P
    Initial release date: 12/1/2025
    Expiration date: 12/1/2026
    Additional CPE details can be found here.

    Follow CEimpact on Social Media:
    LinkedIn
    Instagram

    Más Menos
    41 m
  • Antibiotic Essentials - New Approvals and Clinical Refreshers
    Nov 24 2025

    Pharmacists play a critical role in infectious disease care, and staying up to date on antibiotic therapies is key to ensuring optimal patient outcomes. This episode reviews recently FDA-approved antibiotics, offers a practical refresher on commonly used antibiotic classes, and highlights frequent side effects—along with strategies for managing them in practice. Tune in to strengthen your clinical knowledge and support safe, effective antibiotic use across care settings.

    HOST
    Joshua Davis Kinsey, PharmD
    VP, Education
    CEimpact

    GUEST
    Hunter Rondeau, PharmD, BCIDP, AAHIVP
    Antimicrobial Stewardship Coordinator
    SSM Health

    Joshua Davis Kinsey has no relevant financial relationships with ineligible companies to disclose.

    Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated.


    CPE REDEMPTION
    This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

    • If you are already enrolled in this course, click here to redeem your credit.
    • To purchase this episode and claim your CPE credit, click here.


    CPE INFORMATION
    Learning Objectives
    Upon successful completion of this knowledge-based activity, participants should be able to:
    1. Identify newly FDA-approved antibiotics and their clinical indications.
    2. Describe commonly used antibiotic classes, their typical side effects, and strategies to manage or mitigate those effects.

    0.05 CEU/0.5 Hr
    UAN: 0107-0000-25-362-H01-P
    Initial release date: 11/24/2025
    Expiration date: 11/24/2026
    Additional CPE details can be found here.

    Follow CEimpact on Social Media:
    LinkedIn
    Instagram

    Más Menos
    42 m
  • Pharmacy's Role with Long-Acting Injectable Medications
    Nov 17 2025

    Discover the benefits of implementing a long-acting injectable (LAI) service at your pharmacy practice site and the impact this service can have on patient care and outcomes. Listen to this week’s episode and learn how to elevate your pharmacy services!

    HOST
    Joshua Davis Kinsey, PharmD
    VP, Education
    CEimpact

    GUEST
    Lindsay McCoy, PharmD, BCPP
    Pharmacy Manager
    Village Drug Shop at Advantage

    CPE REDEMPTION
    This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

    • If you are already enrolled in this course, click here to redeem your credit.
    • To purchase this episode and claim your CPE credit, click here.


    CPE INFORMATION
    Learning Objectives
    Upon successful completion of this knowledge-based activity, participants should be able to:
    1. Analyze the benefits and challenges of implementing a long-acting injectable (LAI) service in a pharmacy practice site.
    2. Discuss how an LAI service can improve patient care, increase financial sustainability, and optimize patient outcomes.

    0.05 CEU/0.5 Hr
    UAN: 0107-0000-25-354-H01-P
    Initial release date: 11/17/2025
    Expiration date: 11/17/2026
    Additional CPE details can be found here.

    Take your pharmacy practice to the next level with our comprehensive course on the administration of long-acting injectables:
    Pharmacy-Based Administration of Long-Acting Injectables: A Sharp Idea
    4 hours | On Demand
    Explore a cutting edge clinical service opportunity with this collection of courses specifically designed to equip pharmacists with the knowledge and skills necessary for the effective management and administration of long-acting injectable medications (LAIs). Course content explores diverse drug profiles, advanced administration techniques, and the strategic implementation of LAI-related services to support the needs of your patients and communities.

    Follow CEimpact on Social Media:
    LinkedIn
    Instagram

    Más Menos
    34 m
adbl_web_global_use_to_activate_DT_webcro_1694_expandible_banner_T1